These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 6127095

  • 1. The cardiovascular and platelet effects of epoprostenol (prostacyclin, PGI2) are unaffected by beta-adrenoceptor blockade in man.
    Hassan S, Pickles H, Fish A, Burke C, Warrington S, O'Grady J.
    Br J Clin Pharmacol; 1982 Sep; 14(3):369-77. PubMed ID: 6127095
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of intravenous infusion of prostacyclin (PGI2) in man.
    O'Grady J, Warrington S, Moti MJ, Bunting S, Flower R, Fowle AS, Higgs EA, Moncada S.
    Prostaglandins; 1980 Feb; 19(2):319-32. PubMed ID: 6992228
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Mechanism of the chronotropic effects of prostacyclin in the dog: comparison with the actions of prostaglandin E2.
    Chiba S, Malik KU.
    J Pharmacol Exp Ther; 1980 May; 213(2):261-6. PubMed ID: 6988574
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of platelet aggregation with intravenous and oral administration of carboprostacyclin in man.
    Karim SM, Adaikan PG, Lau LC, Tai MY.
    Prostaglandins Med; 1981 May; 6(5):521-7. PubMed ID: 7022510
    [Abstract] [Full Text] [Related]

  • 9. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
    Gershlick AH, Spriggins D, Davies SW, Syndercombe Court YD, Timmins J, Timmis AD, Rothman MT, Layton C, Balcon R.
    Br Heart J; 1994 Jan; 71(1):7-15. PubMed ID: 8297699
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cardiovascular and platelet effects in man of BW 245C, a stable mimic of epoprostenol (PGI2).
    Orchard MA, Ritter JM, Shepherd GL, Lewis PJ.
    Br J Clin Pharmacol; 1983 May; 15(5):509-11. PubMed ID: 6344895
    [Abstract] [Full Text] [Related]

  • 18. Effects of prostacyclin on bronchoconstriction and neutropenia induced by inhaled platelet-activating factor in man.
    Lammers JW, Kioumis I, McCusker M, Nichol GM, Barnes PJ, Chung KF.
    J Allergy Clin Immunol; 1990 Apr; 85(4):763-9. PubMed ID: 2109002
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the vasodepressor action of ZK 36 374, a stable prostacyclin derivative, PGI2 and PGE1 with their effect on platelet aggregation and bleeding time in rats.
    Casals-Stenzel J, Buse M, Losert W.
    Prostaglandins Leukot Med; 1983 Feb; 10(2):197-212. PubMed ID: 6189133
    [Abstract] [Full Text] [Related]

  • 20. The effect of intravenous epoprostenol (prostacyclin, PGI2) on cerebral blood flow and cardiac output in man.
    Cook PJ, Maidment CG, Dandona P, Hutton RA, James IM.
    Br J Clin Pharmacol; 1983 Dec; 16(6):707-11. PubMed ID: 6362696
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.